The Clinical Trial Decision Journey.

Patients do not make one clinical trial decision. They make a sequence of decisions, each with different questions, emotions, and readiness requirements.

A decision journey is not a recruitment funnel.

A funnel measures movement toward an organizational outcome. A decision journey explains what the patient must understand, evaluate, and sustain before movement is appropriate. That distinction matters because a patient can advance through clicks, referrals, and pre-screening without becoming more prepared.

The systematic review of patient journeys through clinical trials found that participation is influenced by information, trust, practical burden, relationships, and the experience of care. These conditions change across time. A static funnel cannot show whether the decision is strengthening or becoming more fragile.

Six moments determine whether participation can hold.

1. Awareness: Does the patient recognize clinical research as relevant and credible?
2. Relevance: Can the patient see why this specific study may apply to their condition and circumstances?
3. Evaluation: Can risks, alternatives, uncertainty, procedures, and burden be compared in practical terms?
4. Consent: Is the decision informed, voluntary, and expressed without pressure?
5. Activation: Can the patient complete the handoff, screening, scheduling, and first participation requirements?
6. Sustained participation: Do expectations, support, and feasibility remain aligned as the protocol unfolds?

Consent is essential, but it is one governed transition inside a longer decision system. The patient may need to reconsider feasibility after a new procedure, treatment effect, caregiver change, or accumulating travel burden.

Every transition needs a readiness question.

At awareness, the question is whether the information feels relevant and trustworthy. During evaluation, the question becomes whether the patient can explain the study and compare it with alternatives. Before activation, the question is whether participation can fit daily life. During the study, the question is whether the original decision still feels understandable and sustainable.

These questions turn patient experience into an operational discipline. They reveal why a patient paused, what support is appropriate, and when additional progression would be premature. A clear answer may support moving forward, more preparation, or a confident decision not to participate.

Build the map around decisions, not touchpoints.

A useful journey map records the patient's question, emotional state, information need, practical barrier, trusted influence, and next appropriate action at each stage. It also identifies who owns the response and what evidence confirms that the barrier was resolved.

The map should be created with patients and caregivers, not inferred from internal process. It should be segmented by population and tested against real behavior. Most importantly, it should preserve the patient's ability to pause or decline. The purpose is better decision quality and more durable participation, not faster conversion at any cost.

Sources.

1. FDA, Informed Consent Guidance
2. HHS OHRP, The Belmont Report
3. Houghton et al., Systematic Review of Patient Journeys Through Clinical Trials
4. Systematic Review of Interventions Supporting Decisions About Research Participation

About the author

Rebecca Schelkun

Vice President, Patient Readiness

Rebecca is Vice President of Patient Readiness at Jumo Health. She combines public health expertise in epidemiology and biostatistics with experience across health equity, patient advocacy, pediatrics, rare disease, and clinical trial strategy. At Jumo, she turns protocol demands and lived experience into education, decision support, and expectation alignment patients can use.